Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

Megan Crane, Anchalee Avihingsanon, Reena Rajasuriar, Pushparaj Velayudham, David Iser, Ajantha Solomon, Baotuti Sebolao, Andrew Tran, Tim Spelman, Gail V Matthews, Paul Urquhart Cameron, Pisit Tangkijvanich, Gregory J Dore, Kiat Ruxrungtham, Sharon Ruth Lewin

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)


We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon ? (IFN-?) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-? and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.
Original languageEnglish
Pages (from-to)745 - 751
Number of pages7
JournalThe Journal of Infectious Diseases
Issue number5
Publication statusPublished - 2014

Cite this